Press Release

Sequantrix signs agreement with Ono Pharma for use of the *AI-to-in vivo* platform for drug and target evaluation

Aachen, Germany, September 24, 2026. Sequantrix (SQX) announced today that it signed an agreement with Ono Pharmaceutical Co., Ltd. (Ono), for the use of its *AI-to-in vivo* technology platform for target triage and drug development projects at Ono.

SQX's *AI-to-in vivo* platform integrates proprietary multimodal single-cell and spatial omics data derived from high-quality patient tissues with advanced computational AI capabilities. These are complemented by in silico perturbation tools, organoid-based disease modeling assays, and sophisticated in vivo models to enable end-to-end target discovery and validation.

Under the initial collaboration, SQX will collaborate closely with Ono's research team to validate target candidates nominated by Ono within a defined disease area. In parallel, SQX will leverage its unique in vitro assays which mimic human organ functions and tissue structures to support Ono in the optimization of drug candidates.

"We are delighted to start a collaboration with Ono and deploy some of the capabilities of our AI-to-in vivo platform to support Ono with biologically highly relevant information for their target triage and drug optimisation process," said Michael Rheinnecker, Co-Founder and CEO of SQX. *"We are confident that this partnership will drive the development of innovative therapeutic strategies for a disease with significant unmet medical need."*

About Sequantrix

Sequantrix was created by leading pioneers in fibrosis research, clinical care and computational science to address the large, unmet medical need for anti-fibrotic therapies. The spin-out from the University Hospital Aachen leverages one of the world's largest human multimodal, single-cell datasets in the field of fibrotic diseases to discover and validate novel targets and develop anti-fibrotic drug candidates up to the clinical proof of concept.

Contact: info@sequantrix.bio